Aaltomaa S, Lipponen P, Papinaho S, Syrjänen K
Department of Surgery, University of Kuopio, Finland.
J Cancer Res Clin Oncol. 1993;119(5):288-94. doi: 10.1007/BF01212727.
Proliferating cell nuclear antigen, PCNA (PC10), immunolabelling was determined in 175 women with breast carcinomas and related to other established prognostic factors: flow-cytometric data, volume-corrected mitotic index, sex steroid receptor content and clinical outcome during the mean follow-up of 9 years. The maximum fraction of PCNA-positive nuclei (PCNAmax), the average fraction of positive nuclei (PCNAtot) and the number of intensely stained nuclei per microscope field (PCNAcount) were significantly related to histological grade (P < 0.001), DNA ploidy ((P < 0.001), S-phase fraction (P < 0.001), mitotic index (P < 0.001) and sex steroid receptor content (P = 0.002). PCNAmax (P = 0.015) predicted survival in univariate analysis; PCNAtot (P = 0.025), PCNAmax (P = 0.007) and PCNAcount (P = 0.019) predicted the recurrence-free survival. In axillary-lymph-node-negative tumours, PCNAtot (P = 0.092), PCNAmax (P = 0.036) and PCNAcount (P = 0.006) predicted survival and recurrence-free survival (P = 0.011), (P = 0.012) and (P = 0.006) respectively. In multivariate analysis including clinical, histological, flow-cytometric and biochemical variables, PCNAtot (P = 0.004) predicted the recurrence-free survival independently. In axillary-lymph-node-negative breast cancers, PCNAtot predicted accurately the patient survival (P = 0.002) and the recurrence-free survival (P = 0.002). The results indicate that PCNA immunolabelling has independent prognostic value particularly in local breast cancer.
在175例乳腺癌女性患者中测定了增殖细胞核抗原（PCNA，PC10）免疫标记，并将其与其他已确定的预后因素相关联：流式细胞术数据、体积校正有丝分裂指数、性类固醇受体含量以及平均9年随访期间的临床结局。PCNA阳性细胞核的最大比例（PCNAmax）、阳性细胞核的平均比例（PCNAtot）以及每个显微镜视野中强染色细胞核的数量（PCNAcount）与组织学分级（P < 0.001）、DNA倍体（P < 0.001）、S期比例（P < 0.001）、有丝分裂指数（P < 0.001）和性类固醇受体含量（P = 0.002）显著相关。PCNAmax（P = 0.015）在单变量分析中预测生存情况；PCNAtot（P = 0.025）、PCNAmax（P = 0.007）和PCNAcount（P = 0.019）预测无复发生存情况。在腋窝淋巴结阴性肿瘤中，PCNAtot（P = 0.092）、PCNAmax（P = 0.036）和PCNAcount（P = 0.006）分别预测生存情况和无复发生存情况（P = 0.011）、（P = 0.012）和（P = 0.006）。在包括临床、组织学、流式细胞术和生化变量的多变量分析中，PCNAtot（P = 0.004）独立预测无复发生存情况。在腋窝淋巴结阴性乳腺癌中，PCNAtot准确预测患者生存情况（P = 0.002）和无复发生存情况（P = 0.002）。结果表明，PCNA免疫标记具有独立的预后价值，尤其在局部乳腺癌中。
